Needham Reiterates Buy Rating on Taysha Gene Therapies
Needham maintains its buy rating for Taysha Gene Therapies with a $12 price target, a 76.21% upside from the current price.
Key Points
- Needham analyst Gil Blum reiterated a buy rating on Taysha Gene Therapies, Inc. (TSHA) on June 30, 2026, with a $12 price target.
- Needham's $12 price target implies 76.21% upside from Taysha Gene Therapies, Inc.'s ($TSHA) current $6.81 share price.
- Shares of TSHA traded at $6.73 on Wednesday, with a market cap of approximately $1.82 billion and a 52-week range between $2.25 and $7.30.
- Other analysts also maintain buy ratings, with price targets ranging from $10 to $17, reflecting strong interest in Taysha's potential.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Needham analyst Gil Blum has reiterated a buy rating on Taysha Gene Therapies, Inc. (NasdaqGS: TSHA), setting a price target of $12. This update was made on June 30, 2026, and reflects ongoing confidence in the company's prospects.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Taysha Gene Therapies, Inc. Stock Up 18.0%
Shares of Taysha Gene Therapies traded at $6.73 on Wednesday. The company, with a market cap of approximately $1.82 billion, operates in the biotechnology sector. It has a 52-week low of $2.25 and a high of $7.30. The stock's 50-day moving average is $6.13, and the 200-day moving average is $4.97. Taysha's current ratio stands at 14.04, with a quick ratio of 13.76 and a debt-to-equity ratio of 32.34.
$TSHA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Taysha Gene Therapies reported revenue of $7.47 million. However, the company is not yet profitable, reflected in its negative forward P/E ratio of -14.41. The return on equity is also negative at -97.28%. The next earnings date is anticipated to be August 12, 2026.
Insider Buying and Selling at Taysha Gene Therapies, Inc.
Recent insider activity includes purchases by John Stalfort III, Alison Long, and Laura Sepp-Lorenzino, each acquiring 42,671 shares on June 1, 2026. Additionally, Laura Sepp-Lorenzino and John Stalfort III each bought 21,335 shares on the same day. Phillip Donenberg also purchased 21,335 shares.
Analysts Set New Price Targets
On June 30, 2026, Needham maintained its buy rating for Taysha Gene Therapies with a $12 price target. Baird also maintained a buy rating with a $15 target. Earlier in June, BMO Capital, B of A Securities, and Citizens reiterated their buy ratings with price targets of $14, $10, and $11, respectively. The consensus among analysts is a strong buy, with an average target price of $12.85 across 13 analyst opinions.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc. is a biotechnology company based in Dallas, Texas. It focuses on the development and commercialization of gene therapies for severe monogenic diseases of the central nervous system. Led by CEO Sean P. Nolan, the company is working on treatments for conditions such as giant axonal neuropathy and Rett syndrome, among others. Taysha collaborates with The University of Texas Southwestern Medical Center and employs around 99 people.
Bottom Line
Needham's reiterated buy rating highlights confidence in Taysha Gene Therapies' potential within the biotechnology field. Investors often track such analyst updates for insights into market sentiment and potential stock performance. It's important to remember that these ratings are based on available data at the time of the report and may not reflect future changes.
Get Taysha Gene Therapies, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TSHA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.